Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 15.10 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market Analysis
The Asia-Pacific ovarian cancer diagnostics and therapeutics market is expected to register a CAGR of 15.1% during the forecast period.
- The COVID-19 pandemic significantly impacted the market studied. A cancer diagnosis had been delayed as screening programs and diagnostic services were reduced or halted in Asia-Pacific countries due to the fear of acquiring COVID-19 infection. In February 2021, a research study published in the Journal of Ovarian Research stated that the COVID-19 pandemic imposed excessive burdens on the healthcare system, leading to treatment cancellations and delayed surgeries. In light of the pandemic condition, the management strategy for ovarian cancer patients was modified and created by the pathological type, tumor stage, and the present stage of treatment. Hence, this led to a slight decline in the market during the early phases of the pandemic. Therefore, the market was impacted negatively during the pandemic. Still, it is expected to see a surge post-pandemic. It is anticipated to reach the pre-pandemic levels by the end of 2023 due to the increased adoption of surgeries that were postponed during the pandemic phase.
- Factors such as the increasing incidence of ovarian cancer, the increasing population of aged women, and the increase in healthcare expenditure in developing countries are expected to increase market growth. For instance, According to the Government of Australia 2022, it is estimated that 1,815 new cases of ovarian cancer (including serious carcinomas of the fallopian tube) have been diagnosed in Australia in 2022. Furthermore, according to the news in February 2021, Ovarian cancer incidence in India is between 5.4 and 8 per 100,000 people. Such a huge incidence of ovarian cancers in Asian countries is expected to drive market growth due to increased adoption of diagnosis and treatment.
- The rising initiatives from the cancer institutes, such as partnerships, are anticipated to drive market growth. For Instance, In July 2021, the Cancer Institute and the Indian Institute of Technology-Madras entered into a partnership to develop a kit for the early diagnosis of ovarian cancer. The aim is to develop a cost-effective, point-of-care device that will use only a blood sample and can be deployed for outpatient diagnosis.
- With funds from the Department of Science and Technology, the institute studied 138 ovarian cancer patients, 20 patients with benign ovarian cancers, and 238 healthy patients as the control group. The study used high-end proteomics to identify proteins that were expressed differentially in the epithelial ovarian cancers that account for over 90% of all ovarian cancers. Hence, such collaborations will increase market growth in the upcoming future.
- Initiatives by the government are another factor in market growth. For instance, in August 2021, the non-profit organization Cancer Research Malaysia (CRM) showed the feasibility of mainstreaming or implementing genetic testing and genetic counseling for improved diagnosis and treatment of ovarian cancer. This makes Malaysia one of the first countries in Asia to have access to genetic testing for faulty breast cancer susceptibility (BRCA) genes responsible for the devastating disease. Hence, the abovementioned factors are expected to increase the market share.
- Therefore, factors such as the rising incidence of ovarian cancers, rising initiatives from the key market players, and increased initiatives from the government are expected to drive the market growth. However, the lack of skilled professionals in the region is likely to hinder market growth.
Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market Trends
Positron Emission Tomography is Expected to Hold a Significant Market Share Over the Forecast Period
- The rise in demand for positron emission tomography (PET) analysis in the diagnosis of ovarian cancer and the rising initiatives from the key market players are the factors responsible for driving the growth of the segment.
- According to the study published in Quantitative Imaging in Medicine and Surgery in March 2021 in China, PET/CT (computed tomography) scans accurately predicted peritoneal metastases with high sensitivity (84.2%), specificity (87.0%), and accuracy (85.1%) in advanced ovarian cancer before surgery. Such studies show the importance of PET scanning for ovarian cancer, thereby leading to increased adoption and driving segment growth.
- The huge investments by universities for the procurement of PET scanners are one of the factors driving the market growth. For instance, in March 2021, a USD 15 million project was proposed by the University of Sydney in a joint venture with the Northern Sydney Local Health District to procure a total-body PET scanner in Australia. This TB-PET scanner project will revolutionize Australia's biomedical imaging capabilities, deliver improved patient outcomes, and boost medical and health science research programs, driving market growth.
- Many radioisotopes and nuclear imaging equipment manufacturers are developing advanced technology for PET imaging for cancer and other diseases, also boosting the studied market. For instance, in May 2021, United Imaging, a China-based company involved in medical imaging and radiotherapy equipment, launched its uExcel Technology Platform for PET/CT at the China International Medical Equipment Fair (CMEF). Therefore, the rising innovative technologies in PET scanning help in the increased adoption of these scanners for ovarian cancer, driving the market growth.
- Hence, factors such as rising initiatives from key market players, such as investments and launches, are responsible for driving the growth of the market studied in the forecast period.
China is Expected to Hold a Healthy Share in the Market Over the Forecast Period
- The major factors fueling the market growth in the country are the increasing burden of ovarian cancer disorder, the growing focus on research and development of effective cancer therapies, and the rising number of product approvals, along with increasing investment.
- The rising incidence of ovarian cancers in the country is anticipated to drive market growth. For instance, in March 2021, a research study published in BMC Women's Health stated that the incidence and mortality of ovarian cancer have shown a fast-increasing trend in China. Hence, increasing ovarian cancer will increase the demand for diagnostics and therapeutics, which will increase the market growth in the region.
- Also, the research and developments accompanied by drug approvals in China are expected to drive market growth in the country due to the increased availability of ovarian cancer therapeutics. For instance, in May 2021, BeiGene, Ltd. received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of patients with germline BRCA (gBRCA) mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer. Furthermore, in May 2022, Zai Lab Limited presented the analysis of the Phase III PRIME study exploring the efficacy of niraparib maintenance therapy for patients in China with advanced ovarian cancer based on their response to first-line platinum-based chemotherapy.
- Hence, the abovementioned factors, such as the increasing incidence of ovarian cancers and rising approvals of ovarian cancer drugs in China, are expected to increase market growth in the region.
Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Industry Overview
The market for Asia-Pacific ovarian cancer diagnostics and therapeutics market is highly competitive due to the presence of a huge number of market players. The factors owing to the competition include rising product launches and rising partnerships in the development of ovarian cancer therapeutics, among others. Some of the companies that are currently dominating the market are AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and GlaxoSmithKline Plc, among others.
Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market Leaders
-
Eli Lilly and Company
-
Bristol-Myers Squibb Company
-
F. Hoffmann-La Roche Ltd
-
AstraZeneca
-
Glaxosmithkline Plc
*Disclaimer: Major Players sorted in no particular order
Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market News
- September 2022: Takeda Korea launched its PARP inhibitor, Zejula (niraparib), which confirmed the continuous and long-term progression-free survival (PFS) and disease resolution in the primary maintenance treatment of newly diagnosed patients with progressive ovarian cancer.
- September 2022: National Medical Products Administration in China officially approved PARP inhibitor Lipuzo jointly developed by AstraZeneca and Merck for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Burden of Ovarian Cancer
- 4.2.2 Increasing Population of Aged Women
- 4.2.3 Increase in Healthcare Expenditure in Developing Countries
-
4.3 Market Restraints
- 4.3.1 Lack of Skilled Professionals
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Cancer Type
- 5.1.1 Epithelial Ovarian Tumors
- 5.1.2 Ovarian Germ Cell Tumors
- 5.1.3 Ovarian Stromal Tumors
- 5.1.4 Primary Peritoneal Carcinoma
-
5.2 By Diagnosis
- 5.2.1 Blood Tests
- 5.2.2 PET
- 5.2.3 CT Scan
- 5.2.4 Other Diagnoses)
-
5.3 By Treatment
- 5.3.1 Chemotherapy
- 5.3.2 Immunotherapy
- 5.3.3 Radiation Therapy
- 5.3.4 Other Treatments
-
5.4 Geography
- 5.4.1 China
- 5.4.2 Japan
- 5.4.3 India
- 5.4.4 Australia
- 5.4.5 South Korea
- 5.4.6 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Almac Group
- 6.1.2 AstraZeneca
- 6.1.3 BDR Pharmaceuticals Internationals Pvt. Ltd
- 6.1.4 Bristol-Myers Squibb Company
- 6.1.5 Eli Lilly and Company
- 6.1.6 F. Hoffmann-La Roche Ltd
- 6.1.7 Glaxosmithkline Plc
- 6.1.8 Janssen Pharmaceuticals, Inc.
- 6.1.9 Quest Diagnostics
- 6.1.10 Siemens Healthineers AG
- 6.1.11 Takeda Pharmaceutical Company
- 6.1.12 United Imaging
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAsia-Pacific Ovarian Cancer Diagnostics and Therapeutics Industry Segmentation
As per the scope, ovarian cancer is the abnormal growth of cells that form in the ovaries. The cells multiply quickly and can invade and destroy healthy body tissue. Ovarian cancer treatment usually involves surgery and chemotherapy. The market includes both diagnostics and therapeutics products.
The Asia-Pacific ovarian cancer diagnostics and therapeutics market is segmented by cancer type (epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors, and primary peritoneal carcinoma), diagnosis (blood tests, PET, CT scan, and other diagnoses), treatment (chemotherapy, immunotherapy, radiation therapy, and other treatments), and geography (China, Japan, India, Australia, South Korea and Rest of Asia-Pacific).
The report offers the value (in USD) for the above segments.
| By Cancer Type | Epithelial Ovarian Tumors |
| Ovarian Germ Cell Tumors | |
| Ovarian Stromal Tumors | |
| Primary Peritoneal Carcinoma | |
| By Diagnosis | Blood Tests |
| PET | |
| CT Scan | |
| Other Diagnoses) | |
| By Treatment | Chemotherapy |
| Immunotherapy | |
| Radiation Therapy | |
| Other Treatments | |
| Geography | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific |
Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market Research FAQs
What is the current Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market size?
The Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market is projected to register a CAGR of 15.10% during the forecast period (2024-2029)
Who are the key players in Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market?
Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, AstraZeneca and Glaxosmithkline Plc are the major companies operating in the Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market.
What years does this Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market cover?
The report covers the Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
APAC Ovarian Cancer Diagnostics and Therapeutics Industry Report
Statistics for the 2024 APAC Ovarian Cancer Diagnostics and Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. APAC Ovarian Cancer Diagnostics and Therapeutics analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
